Pharmaxis has two respiratory products, Bronchitol® and Aridol®, approved in various world markets. Both products are Australian discoveries, developed by Pharmaxis and now manufactured for global markets at the Company’s purpose- built, high tech production and testing facility in Sydney Australia.
Bronchitol® for the treatment of cystic fibrosis was the subject of three large scale clinical trials and is approved and marketed in Europe, Russia, Australia and the United States.
Aridol® is a bronchial challenge test for the diagnosis and assessment of asthma. It is approved and marketed in the United States, Europe, Australia, Canada and Asia.